Janux Therapeutics Inc (JANX)
47.49
+0.01
(+0.02%)
USD |
NASDAQ |
May 16, 16:00
47.49
0.00 (0.00%)
After-Hours: 20:00
Janux Therapeutics Cash from Financing (Quarterly): 322.17M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 322.17M |
| December 31, 2023 | 0.831M |
| September 30, 2023 | 56.61M |
| June 30, 2023 | 0.528M |
| March 31, 2023 | 1.58M |
| December 31, 2022 | 0.191M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.308M |
| March 31, 2022 | 0.001M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.164M |
| September 30, 2021 | -0.843M |
| June 30, 2021 | 329.66M |
| March 31, 2021 | 57.55M |
| December 31, 2020 | 4.553M |
| September 30, 2020 | -0.033M |
| June 30, 2020 | 5.50M |
| March 31, 2020 | 1.504M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.843M
Minimum
Sep 2021
329.66M
Maximum
Jun 2021
45.90M
Average
0.831M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
| Viking Therapeutics Inc | 606.04M |
| Equillium Inc | 0.00 |
| Minerva Neurosciences Inc | 0.00 |
| Arvinas Inc | 1.60M |
| Calidi Biotherapeutics Inc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.84M |
| Cash from Investing (Quarterly) | -113.74M |
| Free Cash Flow | -53.26M |
| Free Cash Flow Per Share (Quarterly) | -0.3065 |
| Free Cash Flow to Equity (Quarterly) | -15.03M |
| Free Cash Flow Yield | -2.45% |